\nThe increasing clinical use of the Swoop\u00ae system is driven by several factors: enhanced clinical utility from improved image quality, growing evidence of its economic value, and expanding adoption across new care settings, including neurology clinics and the emergency department (ED). The most successful Swoop\u00ae system programs are driven by visionary healthcare leaders who are passionate about addressing the challenges of MRI availability and recognize the clinical and economic value of portable MRI in expanding patient access to imaging.<\/p>\n
\nJennifer Villa Frabizzio, MD, Chief of Neuroradiology at Jefferson Abington Hospital, who has used the Swoop\u00ae system for over three years, commented, \u201cWe are excited to have surpassed one thousand Swoop\u00ae system scans, making us the highest volume center in the United States. Since we have such a robust Swoop\u00ae system program, we decided to evaluate the impact to our hospital, which was recently published in a peer-reviewed journal. We were impressed to find that increasing access to imaging with the Swoop\u00ae system not only improved patient care but also delivered meaningful cost savings, significantly reduced MRI wait times in the ICU and ED, and improved patient progression throughout the hospital. Recently, we have also started using the Swoop\u00ae system for outpatient brain MRI to reduce wait times for patients at outpatient clinics.\u201d As healthcare systems face mounting pressure to improve both efficiency and quality of care, Jefferson Abington’s experience provides compelling evidence that portable brain MRI offers strong clinical utility and a favorable health economic profile, particularly at scale.<\/p>\n
\nCHRISTUS Mother Frances, one of the first sites to adopt the next-generation Swoop\u00ae system, crossed the 500-scan milestone in just nine months, driven by integrating the Swoop\u00ae system into a scalable stroke program. As adoption continues to accelerate, Chief Medical Officer at the center, Mark Anderson, MD, shared, \u201cThe Swoop\u00ae system has had such a big impact improving patient care and hospital efficiency with our stroke patients in the main hospital ED, we purchased an additional system to place in a satellite ED to help triage stroke patients \u2013 enabling faster patient care and avoiding unnecessary admissions and transport costs. We are also pioneering use in the operating room, becoming the first in the United States to conduct transsphenoidal tumor resection using the Swoop\u00ae system pre- and post-operatively to confirm surgical success.\u201d<\/p>\n
\nClinical use of the Swoop\u00ae system is accelerating in neurology offices, where it has quickly become a valuable extension of the diagnostic workflow since its introduction in mid-2025. Neurology of Central Florida has already exceeded 500 in-office MRI scans, demonstrating how point-of-care imaging enables neurologists to complete diagnostic evaluations within their own practice. As Alicia Cabrera, MD, noted, \u201cThe Swoop\u00ae System is an excellent tool to expedite the diagnostic process\u2014it\u2019s the missing link we didn\u2019t have before. Patients used to wait weeks for imaging and results; now we can often get answers within 24 to 72 hours, allowing faster decisions and helping avoid unnecessary emergency room visits.\u201d The Swoop\u00ae system provides a more comfortable and convenient patient experience, supported by NEURO PMR findings showing a 4:1 patient preference for portable MRI. It is now routinely used for outpatient applications, including headache, dementia, multiple sclerosis surveillance, and emerging brain health assessments.<\/p>\n
\n\u201cThe experiences at Jefferson Abington, CHRISTUS Mother Frances, and Neurology of Central Florida reflect what we hear consistently from clinicians\u2014timely access to MRI remains a meaningful challenge and portable MRI is helping address that need,\u201d said Maria Sainz, President and CEO of Hyperfine. \u201cBy eliminating the barriers that have long defined conventional MRI\u2014wait times, technologist shortages, cost, and immobility\u2014the Swoop\u00ae system enables faster decision-making across the hospital and beyond. At Hyperfine, we have redefined what MRI delivery looks like, and we remain committed to supporting brain health by making high-quality imaging available to more patients across more care settings.\u201d<\/p>\n
\nHear more from these hospital centers in our recent webinar<\/a> on how portable MRI is transforming stroke care.<\/p>\n \nFor more information about the Swoop\u00ae system, please visit HyperfineMRI.com<\/a>.<\/p>\n About the Swoop\u00ae Portable MRI Systems About Hyperfine, Inc. \nHyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.<\/p>\n Forward-Looking Statements View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260618936203\/en\/<\/a><\/span><\/p>\n Media Contact Investor Contact KEYWORDS:<\/b> Connecticut United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Technology Medical Devices FDA Neurology Hospitals Health Technology Software Health Artificial Intelligence<\/p>\n
\n
<\/b>The Swoop\u00ae Portable MR Imaging\u00ae Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.<\/p>\n
\n
<\/b>Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com<\/a>.<\/p>\n
\n
<\/b>This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the \u201cCompany\u201d) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company\u2019s goals and commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae system is accepted and used by healthcare professionals; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future ; the inability of the Company to progress on product advancements and improvements ; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; existing and potential future National Institutes of Health funding pressures; existing and potential future effects from U.S. export controls and tariffs; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in the Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n<\/p>\n
\n
<\/b>Devin Zell
\n
Hyperfine
\n
dzell@hyperfine.io<\/a><\/p>\n
\n
<\/b>Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260618936203\/en\/2375273\/3\/Hyperfine_Logomark_Full_Color_RGB_600px_tall.jpg\")
<\/td>\n<\/tr>\n